Molecular Endotypes of Chronic Idiopathic Urticaria
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU)
respond to treatment with omalizumab (Xolair). It will test people before they receive
treatment with omalizumab as part of standard of care, to see if there are differences in
their blood and skin that can predict who responds to treatment.